| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.2 | 4e-05 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.0003 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0004 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0004 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0006 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0006 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0009 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |